JP4747579B2 - アトピー性皮膚炎の予防・治療剤 - Google Patents
アトピー性皮膚炎の予防・治療剤 Download PDFInfo
- Publication number
- JP4747579B2 JP4747579B2 JP2005000303A JP2005000303A JP4747579B2 JP 4747579 B2 JP4747579 B2 JP 4747579B2 JP 2005000303 A JP2005000303 A JP 2005000303A JP 2005000303 A JP2005000303 A JP 2005000303A JP 4747579 B2 JP4747579 B2 JP 4747579B2
- Authority
- JP
- Japan
- Prior art keywords
- atopic dermatitis
- jifushi
- agent
- present
- inchinkou
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 201000008937 atopic dermatitis Diseases 0.000 title claims description 25
- 206010012438 Dermatitis atopic Diseases 0.000 title claims description 24
- 239000003814 drug Substances 0.000 title claims description 8
- 229940124597 therapeutic agent Drugs 0.000 title claims description 4
- 230000003449 preventive effect Effects 0.000 title description 3
- 208000003251 Pruritus Diseases 0.000 claims description 20
- 229940125714 antidiarrheal agent Drugs 0.000 claims description 10
- 239000003793 antidiarrheal agent Substances 0.000 claims description 10
- 241000208340 Araliaceae Species 0.000 claims description 9
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 9
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 9
- 235000008434 ginseng Nutrition 0.000 claims description 9
- 239000003908 antipruritic agent Substances 0.000 claims description 7
- 230000000069 prophylactic effect Effects 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 15
- 230000002393 scratching effect Effects 0.000 description 15
- 238000006748 scratching Methods 0.000 description 14
- 230000006399 behavior Effects 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 8
- 230000001139 anti-pruritic effect Effects 0.000 description 8
- 230000007803 itching Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000002269 spontaneous effect Effects 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 239000000043 antiallergic agent Substances 0.000 description 3
- 229940125715 antihistaminic agent Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000237509 Patinopecten sp. Species 0.000 description 1
- 206010037083 Prurigo Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- 208000037851 severe atopic dermatitis Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Description
「ジフシ(地膚子)」は、アカザ科のホウキギの乾燥果実であり、本発明においては乾燥物でも抽出物でもよい。水、エタノール、プロピレングリコール、1,3−ブチレングリコールまたはこれらの混液を抽出溶媒として、ジフシ抽出物を得ることができる。
インチンコウ 100g
ジフシ 100g
乳糖 1700g
微結晶セルロース 500g
低置換ヒドロキシプロピルセルロース 500g
タルク 50g
硬化ヒマシ油 50g
上記の各成分及び分量を秤量し均一に混合した後、得られた混合粉末を直打法により1錠重量300mgになるように打錠して錠剤を得た。
インチンコウ 50g
ジフシ 50g
乳糖 400g
微結晶セルロース 450g
タルク 50g
上記の各成分及び分量を秤量し均一に混合した後、得られた混合粉末を1号硬カプセルに250mgずつ充填し、カプセル剤を得た。
インチンコウ 10g
ジフシ 10g
エラグ酸ナトリウム 5g
ヒアルロン酸ナトリウム 3g
メチルパラベン 2g
精製水 204g
流動パラフィン(#70) 50g
スクワラン 100g
セトステアリルアルコール 60g
蜜蝋 20g
モノステアリン酸グリセリン 15g
ソルビタンモノラウレート 20g
プロピルパラベン 1g
上記の成分をそれぞれ混合し均一に乳化し、更に香料を適量加えクリーム剤500gを得た。
(試験方法)
試験動物は体重約30gのNC/Nga系雄性マウス、1群8匹を用いた。マウスは発症している動物と1週間同居させ、掻破行動を誘起させた。
自発性掻破行動数はニューロサイエンス社製の掻痒測定システム(NS-SCT16)を用いて測定した。上記動物の後肢にスクラッチ測定用マグネットを挿入し、1匹ずつ測定用ケージに入れ、溶媒(0.2%CMC溶液)経口投与後掻破行動数を24時間測定した(pre値)。その後、各薬剤を経口投与し、再び掻破行動数を24時間測定した(post値)。各生薬エキスは50%エタノール抽出物を用い、0.2%CMC溶液に用時懸濁した。得られた波形は、スクラッチ計測・解析用ソフトウェアにより1.5秒以上の足の動きを1回の掻破行動として数値化し、統計解析処理を行い、pre値、post値間の有意差検定を行った。
なお、デキサメタゾンはステロイド剤であり、本発明の止痒剤と比較するために投与した。
結果を表1及び図1〜5に示した。
Claims (4)
- インチンコウ及びジフシを含有することを特徴とする止痒剤。
- インチンコウ及びジフシを含有することを特徴とするアレルギー性疾患に起因する掻痒感に対する止痒剤。
- インチンコウ及びジフシを含有することを特徴とするアトピー性皮膚炎に起因する掻痒感に対する止痒剤。
- インチンコウ及びジフシを含有することを特徴とするアトピー性皮膚炎の予防または治療剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005000303A JP4747579B2 (ja) | 2004-01-09 | 2005-01-05 | アトピー性皮膚炎の予防・治療剤 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004004135 | 2004-01-09 | ||
JP2004004135 | 2004-01-09 | ||
JP2005000303A JP4747579B2 (ja) | 2004-01-09 | 2005-01-05 | アトピー性皮膚炎の予防・治療剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005220128A JP2005220128A (ja) | 2005-08-18 |
JP4747579B2 true JP4747579B2 (ja) | 2011-08-17 |
Family
ID=34996037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005000303A Expired - Fee Related JP4747579B2 (ja) | 2004-01-09 | 2005-01-05 | アトピー性皮膚炎の予防・治療剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4747579B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102670736A (zh) * | 2012-05-23 | 2012-09-19 | 成肃龙 | 治疗多种皮肤病的外用药膏 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10245395A (ja) * | 1997-03-03 | 1998-09-14 | Dainippon Pharmaceut Co Ltd | 地膚子由来抗掻痒剤 |
JP2000103718A (ja) * | 1998-09-28 | 2000-04-11 | Pola Chem Ind Inc | 生体活動改善用の組成物 |
JP2002029990A (ja) * | 2000-07-12 | 2002-01-29 | Kanebo Ltd | 外用抗掻痒剤 |
-
2005
- 2005-01-05 JP JP2005000303A patent/JP4747579B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2005220128A (ja) | 2005-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6891385B2 (ja) | トラジピタントによる治療方法 | |
US4590213A (en) | Anti-anxiety method | |
JP2017506241A (ja) | ウコンならびにホソババレンギクの抽出物を含有する、末梢性炎症ならびに疼痛の軽減に有用な組成物 | |
JPWO2017111069A1 (ja) | 止痒剤 | |
JP4747579B2 (ja) | アトピー性皮膚炎の予防・治療剤 | |
JP2006501214A (ja) | 発酵小麦胚芽抽出物の抗炎症剤としての使用 | |
KR100809584B1 (ko) | 글루코사민과 피니톨을 유효성분으로 하는 염증성 질환의예방 및 치료용 조성물 | |
CN111148517A (zh) | 用于预防或治疗特应性皮炎的组合物 | |
JP4355967B2 (ja) | 医薬組成物 | |
WO1995028177A1 (fr) | Composition medicinale destinee a traiter la dyskinesie tardive et utilisation de ladite composition | |
EP2727595B1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
JP4706174B2 (ja) | α−グルコシダーゼ阻害剤 | |
JP2005162745A (ja) | 高血圧改善剤 | |
JP4080350B2 (ja) | ビタミンuと硫黄含有酵母からなる抗関節炎食品 | |
JP2005247842A (ja) | 乾皮症治療剤 | |
JP4728570B2 (ja) | レプチン産生抑制剤 | |
JP2010047518A (ja) | 鼻閉抑制剤 | |
JP2010047566A (ja) | 医薬組成物 | |
JP2017014198A (ja) | 脊髄小脳変性症における運動失調の治療剤の投与レジメン | |
JPH1129488A (ja) | ピコスルファートナトリウムを含有する医薬組成物 | |
JP4221267B2 (ja) | 痒みを抑制するための薬剤 | |
JP6641626B2 (ja) | 制酸用医薬組成物 | |
JP2017095369A (ja) | 掻痒改善剤 | |
EP3315128B1 (en) | Dosing regimen of rovatirelin for ataxia associated with spinocerebellar degeneration | |
US20200093880A1 (en) | Compositions and methods for sleep disorders and restless leg syndromes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071219 |
|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090605 |
|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090624 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110419 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110502 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4747579 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140527 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140527 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |